Kura Oncology

Clinical-stage oncology company developing precision medicines targeting menin inhibition and farnesyl transferase for acute leukemias and head/neck cancer. Lead candidates ziftomenib (menin inhibitor) and tipifarnib (FTI) address genetically defined patient populations with high unmet need.